salmeterol,
salmeterol xinafoate,
Serevent,
Xinafoate, Salmeterol,
salmeterol xinafoate,
94749-08-3,
Salmetedur,
Arial,
Serevent diskus,
GR 33343X xinafoate,
Asmerole,
Betamican,
Dilamax,
Inaspir,
Ultrabeta,
Beglan,
Salmeterol (xinafoate),
Salmeterol 1-hydroxy-2-naphthoate,
Serevent Inhaler and Disks,
4-(1-Hydroxy-2-((6-(4-phenylbutoxy)hexyl)amino)ethyl)-2-(hydroxymethyl)phenol 1-hydroxy-2-naphthoate,
GR 33343 G,
Salmeterol xinafonate,
MFCD00897708,
NCGC00094372-03,
DSSTox_CID_25798,
DSSTox_RID_81137,
DSSTox_GSID_45798,
(+-)-4-Hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-m-xylene-alpha,alpha'-diol 1-hydroxy-2-naphthoate (salt),
(+/-) 4-Hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]m-ethyl]-1,3-benzenedimethanol xinafoate,
1,3-Benzenedimethanol, 4-hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-, (+-)-, 1-hydroxy-2-naphthalenecarboxylate (salt),
2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol; 1-hydroxynaphthalene-2-carboxylic acid,
2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol;1-hydroxynaphthalene-2-carboxylic acid,
SMR000875207,
CAS-94749-08-3,
Salmeterol xinafoate [USAN],
Siduomi,
Salmeterol xinafoate [USAN:USP],
salmeterol-xinafoate,
4-[1-Hydroxy-2-[[6-(4-phenylbutoxy)hexyl]amino]ethyl]-2-(hydroxymethyl)phenol 1-Hydroxy-2-naphthoate,
C25H37NO4.C11H8O3,
SALMETEROLO,
AC1L1LPS,
Salmeterol Hydroxynaphthoate,
SCHEMBL18070,
gr-33343g,
MLS001332577,
MLS001332578,
CHEBI:9012,
CHEMBL1082607,
DTXSID1045798,
C36H45NO7,
CTK8B9015,
Salmeterol xinafoate (JAN/USAN),
HMS2232I16,
HMS3263K22,
HMS3676P13,
BCP04778,
GR 3343G,
salmeterol, 1-hydroxy-2-naphthoate,
Tox21_111270,
Tox21_501100,
ANW-61823,
GR 33343G,
s4296,
SN 408,
AKOS016004957,
Tox21_111270_1,
AN-8181,
CS-1527,
GR-33343 G,
GR-33343-G,
KS-1140,
LP01100,
NCGC00015938-05,
NCGC00094372-01,
NCGC00094372-02,
NCGC00094372-04,
NCGC00261785-01,
4CA-1124,
BC208521,
HY-17453,
LS-94516,
BCP0726000003,
AB0020656,
TC-150568,
EU-0101100,
FT-0642283,
ST24031610,
V1621,
Salmeterol xinafoate, >=98% (HPLC), solid,
D00687,
W-5199,
SR-01000597359,
Q-201697,
SR-01000597359-1,
Salmeterol xinafoate, European Pharmacopoeia (EP) Reference Standard,
Salmeterol xinafoate, United States Pharmacopeia (USP) Reference Standard,
4-Hydroxy-alpha-({[6-(4-phenylbutoxy)hexyl]amino}methyl)-1,3-benzenedimethanol xinafoate,
Salmeterol xinafoate for system suitability, European Pharmacopoeia (EP) Reference Standard,
Salmeterol Xinafoate, Pharmaceutical Secondary Standards; Certified Reference Material,
( inverted exclamation markA) 4-Hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]m-ethyl]-1,3-benzenedimethanol xinafoate,
2-(Hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol 1-hydroxy-2-naphthoate,
4-(1-hydroxy-2-(6-(4-phenylbutoxy)hexylamino)ethyl)-2-(hydroxymethyl)phenol 1-hydroxy-2-naphthoate,
4-Hydroxy-?1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol 1-hydroxy-2-naphthalenecarboxylic acid salt,
4-Hydroxy-|A1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol 1-Hydroxy-2-naphthalenecarboxylic Acid,
Serevent,
Salmeterolxinafoate,
Serevent (TN),
Advair Diskus 100/50,
Advair Diskus 250/50,
Advair Diskus 500/50,
UNII-6EW8Q962A5,
94749-08-3 (xinafoate),
6EW8Q962A5,
CID56801,
ACN-040066,
CS-O-00305,
A3190,
C25-H37-N-O4.C11-H8-O3,
89365-50-4,